Cancer drugs targeting SLC16A1–3 have been developed; for example, the SLC16A1 (MCT1) inhibitor AZD3965 was in a phase I clinical trial in patients with advanced solid tumors or lymphomas [120]. Here, SLC16A1 is linked to cancer.